Skip to main content

Eva Colas Ortega

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Eva Colas Ortega

Institutions of which they are part

Head of group
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

I am principal researcher in the Group of Biomedical Research in Gynecology, where I lead the translational research group. My research interest is to provide solutions for unmet clinical needs in gynecology, mainly in endometrial cancer and endometriosis. We work on biomarker research to provide with innovative solutions and preclinical models to improve personalized medicine.

I am biologist by formation and fully dedicated to endometrial cancer research for the last 16 years. From 2017, I lead my own team in the Group of Biomedical Research in Gynecology (VHIR) and my research focus on the implementation of molecular diagnostics and personalized medicine in gynecology, mainly in endometrial cancer (EC) and endometriosis.
In my career I participated in the development of the first EC patient-derived murine models (PDX), and today, my group owns one of the largest PDX biobanks in Europe, which is used by us, partners and pharma to assess treatments for EC patients. Importantly, I have also grown as a scientist dedicated to biomarker research in gynecological fluids. I worked in the development of the first molecular kit to diagnose EC. Today, I am the European Coordinator of a multicenter study to develop a non-invasive diagnosis of EC (ERA PerMed), and am the founder of a spin-off (MiMARK Diagnostics S.L.) that aims to develop innovative solutions for women health.
As a summary, I have a total of 73 scientific articles with impact factor; 17 of them as senior author; and am inventor of 4 patents. My scientific and leadership capacity is proved by the supervision of 12 doctoral theses, 6 of which have already been defended, two of them awarded. I have participated in 32 competitive research projects, being 13 of them principal investigator, and I am actively participating in national (CIBERONC) and international (ENITEC) cancer networks.
I have been teaching in graduate and master studies for the last 7 years; and I have been on the Steering Committee of the Societat Catalana de Biologia for 10 years.

Projects

xx

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Carina Masferrer Ferragutcasas, Fco Javier De la Torre Fdez de Vega, Silvia Cabrera Diaz, Ana Luzarraga Aznar, Lourdes Elena Salazar Huayna
Funding agency: Instituto de Salud Carlos III
Funding: 177500
Reference: PI23/01470
Duration: 01/01/2024 - 31/12/2026

Cytomark, desenvolupament d'un test de diagnòstic no invasiu de càncer d'endometri.

IP: Eva Colas Ortega
Collaborators: Melek Denizli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 100000
Reference: 2021 PROD 00061
Duration: 19/10/2022 - 18/04/2024

Firmas de proteínas en aspirados uterinos para mejorar el diagnóstico de cáncer de endometrio "El proyecto CEMARK".

IP: Eva Colas Ortega
Collaborators: -
Funding agency: Fundación Banco Bilbao Vizcaya Argentaria
Funding: 40000
Reference: BBVA/LEONARDO/2022
Duration: 31/10/2022 - 30/04/2024

Recerca biomèdica en ginecologia

IP: Eva Colas Ortega
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 308600
Reference: CP22/00147
Duration: 01/03/2023 - 29/02/2028

Related news

From 6th to 7th March, more than 60 European researchers have shared the advances in translational research in endometrial cancer

On January 24, a session was held to explain what these three-dimensional models are and what advantages they have, as well as to review some of their applications in research.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

Related professionals

Pere Canals Canals

Pere Canals Canals

Predoctoral researcher
Stroke research
Read more
Ester Sanchez Gavilan

Ester Sanchez Gavilan

Research technician
Stroke research
Read more
Aroa Ruiz Muñoz

Aroa Ruiz Muñoz

Research technician
Cardiovascular Diseases
Read more
Lena Nerea Montaña Ernst

Lena Nerea Montaña Ernst

Research technician
Pharmacokinetic Nanoparticles
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.